

7. References

- Abigail S, Mathai E. Ceftazidime resistance among *Klebsiella pneumoniae* in south India. Indian J Med Res. 1995; 102: 53-5.
- Abraham E P, Chain E. An enzyme from bacteria able to destroy penicillin. Nature. 1940; 146: 837.
- Agrawal P, Ghosh A N, Kumar S, Basu B, Kapila K. Prevalence of Extended-spectrum β -lactamases among *Escherichia coli* and *Klebsiella pneumoniae* isolates in a tertiary care hospital. Indian J Path Microbiol. 2008; 51: 139-142.
- Akindele J A, Rotilu I O. Outbreak of neonatal *Klebsiella* septicemia: a review of antimicrobial sensitivities. Afr J Med Sci. 1997; 26: 51-53.
- Al-Hassan H, Mahallawy E I, Amyes S G B. First report of *bla*_{PER-3} in *Acinetobacter baumannii*. L. Int J Antimicrob Agents. 2013; 41: 90-95.
- Al-Agamy M H, El-Din Ashour M S, Wiegand I. First description of CTX-M β -lactamase producing clinical *Escherichia coli* isolates from Egypt. Int J Antimicrob Agents. 2006; 27: 545-8.
- Al-Agamy M H, Shibl A M, Tawfik A F. Prevalence and molecular characterization of Extended-spectrum- β -lactamase producing *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. Ann. Saudi Med. 2009; 29: 253-257.
- Al Benwan, K, Al Sweih N, Rotimi V O. Etiology and antibiotic susceptibility patterns of community and hospital acquired urinary tract infections in a general hospital in Kuwait. Med. Princ. Pract. 2010; 19: 440–446.
- Ambler R P. The structure of β -lactamases. Philos. Trans. R. Soc. Lond. 1980; 289: 321–331.

Ananthakrishnan A N, Kanungo R. Detection of Extended spectrum β -lactamase producers among surgical wound infections and burn patients in JIPMER. *Indian J Med Microbiol.* 2000; 18: 160-65.

Andersson D I, Levin B R. The biological cost of antibiotic resistance. *Curr. Opinion Microbiol.* 1999; 2: 489-493.

Andersson D I. Persistence of antibiotic resistant bacteria. *Current Opinion Microbiol.* 2003, 6:452–456.

Andrea M M D, Arenaa F, Pallecchia L, Rossolinia G M. CTX-M type β -lactamases: A successful story of antibiotic resistance. *Int J Med Microbiol.* 2013; 303; 305-317.

Andriatahina, T., Randrianirina, F., Hariniana, E. R., Talarmin, A., Raobijaona, H. Buisson, Y. and Richard, V. High prevalence of fecal carriage of Extended spectrum β -lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* in a pediatric unit in Madagascar. *BMC Infect. Dis.* 2010. 12: 204.

Aragon L M, Mirelis B, Miro E, Mata C, Gomez L, Rivera A, Coll P, Navarro F. Increase in β -lactam resistant *Proteus mirabilis* strains due to CTX-M and CMY type as well as new VEB and inhibitor resistant TEM type β -lactamases. *J. Antimicrob Chemother.* 2008; 61, 1029–1032.

Astal Z, Shariff F A, Fahd M I. Extended spectrum β -lactamases in *Escherichia coli* isolated from community acquired urinary tract infections in the Gaza strip, Palestine. *Ann Saudi Med.* 2004; 24: 55- 57.

Aubert D, Girlich D. Functional and structural characterization of the genetic environment of Extended spectrum β -lactamase *bla*_{VEB} gene from a *Pseudomonas aeruginosa* isolate obtained in India. *Antimicrob. Agents Chemother.* 2004; 48: 3284-3290.

- Aubert D, Naas T, Nordmann P. Integrase mediated recombination of the *vebI* Gene Cassette Encoding an Extended Spectrum β -Lactamase. Plos One. 2012; 7: 1-12.
- Aubert D, Poirel L, Chevalier J, Leotard S, Pages J M, Nordmann P. Oxacillinase Mediated Resistance to Cefepime and Susceptibility to Ceftazidime in *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 2001; 45: 1615-1620.
- Bailey J, Pinyon J, Anantham S, Hall R. Distribution of the *bla*_{TEM} gene and *bla*_{TEM} containing transposons in commensal *Escherichia coli*. J. Antimicrob. Chemother. 2011; 66: 745–751.
- Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of *Escherichia coli*. J. Infection. 1990; 18: 294–298.
- Bell J M, Turnidge J D. Prevalence of Extended spectrum β – lactamase (ESBL) producing isolates in the Asia pacific region and South Africa: regional results from SENTRY Antimicrobial surveillance program (1998 – 1999). Diagn Microbiol Infect Dis. 2002; 42: 193-198.
- Benouda A, Touzani O, Khairallah M T, Araj G F, Matar GM. First detection of oxacillinase mediated resistance to carbapenems in *Klebsiella pneumoniae* from Morocco. Ann Trop Med Parasitol. 2010; 104: 327-30.
- Bert F, Branger C, Zechovsky N L. Identification of PSE and OXA β -lactamase genes in *Pseudomonas aeruginosa* using PCR restriction fragment length polymorphism. J. Antimicrob Chemother. 2002; 50, 11–18.
- Bert F, Juvin M. Evaluation and updating of Osiris expert system for identification of *Escherichia coli* β -lactam resistance phenotypes. J Clin Microbiol. 2005; 43: 1846-1850.

Bhattacharjee A, Sen M R, Anupurba S, Prakash P, Nath G. Detection of OXA-2 group Extended spectrum β -lactamase producing clinical isolates of *Escherichia coli* from India. J. Antimicro. Chemother. 2007; 60: 703-704.

Bhattacharjee A, Sen M R, Prakash P, Anupurba S. Role of β -lactamase inhibitors in enterobacterial isolates producing Extended spectrum β -lactamases. J. of Antimicrob Chemother. 2008; 61, 309–314.

Bhattacharjee A, Sen M R, Prakash P, Gaur A, Anupurba S, Nath G. Observation on integron carriage among clinical isolates of *Klebsiella pneumoniae* producing Extended spectrum β -lactamases. Ind J Med Microbiol. 2010; 28: 207-210.

Bisson G, Fishman N O, Patel J B, Edelstein P H, Lautenbach E. Extended spectrum β lactamase producing *Escherichia coli* and *Klebsiella* species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol. 2002; 23: 254-60.

Blagui K, Achour S. Nosocomial outbreak of OXA-18 producing *Pseudomonas aeruginosa* in Tunisia. Clin Microbiol Infect. 2007; 13: 794–800.

Bodey G P. Penicillins, Monobactams and Carbapenems. Texas Heai Y Institi de journal. 1990; 17: 315-329.

Bogaerts P, Naas T, Garch F E, Cuzon G, Deplano A, Delaire T, Huang T D, Lissior B, Nordmann P, Glupczynski Y. GES Extended spectrum β -lactamases in *Acinetobacter baumannii* Isolates in Belgium. Antimicrob. Agents Chemother. 2010; 54: 4872-4878.

Bonnet R, Dutour C. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp 240 Gly. *Antimicrob Agents Chemother.* 2001; 45: 2269-2275.

Bonnet R. Growing group of Extended-spectrum β -lactamases: the CTX-M enzymes. *Antimicrob. Agents Chemother.* 2004; 48: 1-14.

Bonnin R A, Potron A, Poirel L, Lecuyer H, Neri R, Nordmann P. PER-7, an Extended spectrum β -lactamase with increased activity toward broad spectrum cephalosporins in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 2011a; 55: 2424–2427.

Bonnin R A, Nordmann P, Potron A, Lecuyer H, Zahar J R, Poirel L. Carbapenem hydrolyzing GES type Extended spectrum β -lactamase in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 2011b; 55: 349–354.

Bonnin R A, Poirel L, Licker M, Nordmann P. Genetic diversity of carbapenem hydrolysing β -lactamases in *Acinetobacter baumannii* from Romanian hospitals. *Clin. Microbiol. Infect.* 2011c; 17: 1524–1528.

Bonnin R A, Poirel L, Carattoli A, Nordmann P. Characterization of an IncFII plasmid encoding NDM-1 from *Escherichia coli* ST131. *Plos One.* 2012; 7: 1-6.

Boucher Y, Labbate M, Koenig J E, Stokes H W. Integrons: mobilizable platforms that promote genetic diversity in bacteria. *Trends Microbiol.* 2007; 15: 301-309.

Bradford P A. Extended spectrum β -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin. Microbiol. Rev.* 2001; 14: 933-51.

- Brasme L, Nordmann P, Fidel, F. Incidence of class A Extended spectrum β -lactamases in Champagne Ardenne (France): a 1 year prospective study. *J Antimicrob. Chemother.* 2007; 60: 956 – 964.
- Breidenstein E B M, Fuente Nunez C D L, Hancock R E W. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol.* 2011; 19: 419-426.
- Brown D F, Andrews J, King A, MacGowan A P. Detection of Extended spectrum β -lactamases with Etest and double disc potentiation methods. *J. Antimicrob. Chemother.* 2000; 46: 327–328.
- Brun-Buisson C, Legrand P, Philippon A. Transferable enzymatic resistance to third generation cephalosporins during nosocomial outbreaks of multiresistant *Klebsiella pneumoniae*. *Lancet* 1987: 302 – 306.
- Brunton J, Clare D, Meier MA. Molecular epidemiology of antibiotic resistance plasmids of *Haemophilus* species and *Neisseria gonorrhoeae*. *Rev Infect Dis.* 1986; 8: 713-24.
- Bush K, Jacoby G A, Medeiros A A. A Functional Classification Scheme for β -Lactamases and Its Correlation with Molecular Structure. *Antimicrob. Agents Chemother.* 1995; 39: 1211–1233.
- Bush K, Jacoby G A, Medeiros A A. An Updated Functional Classification of β -Lactamases. *Antimicrob. Agents Chemother.* 2009; 39: 1211-1233.
- Bush K, Jacoby G A. Updated Functional Classification of β -Lactamases. *Antimicrob. Agents Chemother.* 2010; 54: 969-976.
- Bush K. Characterization of β -lactamases. *Antimicrob. Agents Chemother.* 1989a; 33: 259–263.

Bush K. Classification of β -lactamases: groups 1, 2a, 2b, and 2b9. *Antimicrob. Agents Chemother.* 1989b; 33: 264–270.

Bush K. Classification of β -lactamases: groups 2c, 2d, 2e, 3, and 4. *Antimicrob. Agents Chemother.* 1989c; 33: 271–276.

Bush K. Extended spectrum β -lactamases in North America, 1987–2006. *Clin. Microbiol. Infect.* 2008; 14: 134–143.

Bush K. Is it important to identify ESBL producing isolates? *Eur J clin microb infec dis*; 1996; 15: 361-4.

Bush K. New β - lactamases in gram negative bacteria: diversity and impact on the selection of antimicrobial therapy. *Clin infec die.* 2001; 32: 1085-9.

Cambray G., Guerout A M, Mazel D. Integrons. *Annu. Rev. Genet.* 2010; 44, 141–166.

Canton R, Alba J M G, Galan J C. CTX-M enzymes: origin and diffusion. *Front. Microbiol.* 2012; 3: 1-19.

Canton R, Oliver A., Coque T. M. Epidemiology of Extended spectrum β -lactamase-Producing *Enterobacter* isolates in a Spanish Hospital during a 12 year period. *J Clin Microbiol* 2002; 40: 1237-1243.

Canton R, Perez Vazquez M, Oliver A, Sanchez B, Gutierrez M O, Martinez Ferrer M, Baquero F. Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing. *J. Clin. Microbiol.* 2000; 38: 1339–1346.

Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque T M. Prevalence and spread of Extended spectrum β -lactamase producing *Enterobacteriaceae* in Europe. *Clin. Microbiol Infect. Suppl.* 2008; 1: 144 -53.

Carattoli A, Bertini A, Villa L, Falbo V, Hopkins K L, Threlfall E J. Identification of plasmids by PCR based replicon typing. *J Microbiol. Methods.* 2005; 63: 219-228.

Carattoli A. Resistance plasmid families in *Enterobacteriaceae*. *Antimicrob. Agents Chemother.* 2009; 53: 2227–2238.

Carattoli A. Plasmids and the spread of resistance. *Inter J. Medical Microbiol.* 2013; 303: 298– 304.

Carattoli A. Plasmids in Gram negatives: molecular typing of resistance plasmids. *Int. J. Med. Microbiol.* 2011; 301: 654–658

Casellas J M, Goldberg M. Incidence of strains producing Extended spectrum β - lactamases in Argentina. *Infect.* 1989; 17: 434 – 436.

Castanheira M, Farrell S E, Deshpande M, Mendes R E, Jones R N. Prevalence of β -lactamase encoding genes among *Enterobacteriaceae* bacteremia isolates collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010). *Antimicrob Agents Chemother.* 2013; 57; 3012–3020.

Chagas T P J, Alves R M, Vallim D C, Seki L M, Campos L C, Asensi M D. Diversity of genotypes in CTX-M producing *Klebsiella pneumoniae* isolated in different hospitals in Brazil. *Braz J Infect Dis.* 2011; 15: 420-425.

Chen T, Feng Y, Yuan J L, Qi Y, Cao X Y, Wu Y. Class 1 integrons contributes to antibiotic resistance among clinical isolates of *Escherichia coli* producing Extended spectrum β -lactamases. *Indian J Medical Microbiol.* 2013; 31: 385-389.

Cheng J J, Sun Z, Ye Y, Gao Y F, Li J B, Zhang X J. Characterization of two plasmid encoded cefotaximases found in clinical *Escherichia coli* isolates: CTX-M-65 and a novel enzyme, CTX-M-87. J Medical Microbiol. 2009; 58, 811–815.

Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber M J, Venezia S N. CTX-M-2 and a new CTX-M-39 enzyme are the Major Extended Spectrum β -Lactamases in Multiple *Escherichia coli* Clones isolated in Tel Aviv, Israel. Antimicrob Agents Chemother. 2005; 49: 4745-4750.

Christopher D, Nancy F C C. Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant *Staphylococcus aureus* (MRSA). Clin Med Rev Ther. 2011; 3: 1-24.

Chroma M, Kolar M. Genetic methods for detection of antibiotic resistance: focus on Extended spectrum β -lactamases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010; 154:289–296.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty First Informational Supplement. M100-S21. CLSI, Wayne, PA, USA, 2011.

Collee J G, Fraser A G, Marmion B P. Simmons A Mackie and McCartney, practical Medical Microbiology, 14th edition. Churchill living stone, New York. 1996.

Collis C M, Grammaticopoulos G, Briton J, Stokes H W, Hall R M. Site-specific insertion of gene cassettes into integrons. Mol. Microbiol. 1993; 9: 41–52.

Colom K, Perez J, Alonso R, Aranguiz A F, Larino E, Cisterna R. Simple and reliable multiplex PCR assay for detection of *bla*_{TEM}, *bla*_{SHV} and *bla*_{OXA-1} genes in *Enterobacteriaceae*. FEMS Microbiol Letters. 2003; 223: 147-151.

Coque T M, Baquero F, Canton R. Increasing prevalence of ESBL producing *Enterobacteriaceae* in Europe. Euro Surveill. 2008; 20: 19044.

Coque T M, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, Baquero F, Canton R, Nordmann P. Dissemination of clonally related *E. coli* strains expressing expanded spectrum β lactamase CTX-M-15. Emerg. Infect. Dis. 2008; 14: 195-200.

Cormican M G, Marshall S A, Jones R N. Detection of Extended spectrum β -lactamase (ESBL) producing strains by the E-test ESBL screen. J. Clin. Microbiol. 1996; 34: 1880–1884.

Correia M, Boavida F, Grosso F, Salgado M J, Lito L M, Cristino J M, Mendo S, Duarte A. Molecular characterization of a new class 3 integron in *Klebsiella pneumoniae*. Antimicrob. Agents Chemother. 2003; 47: 2838–2843.

Cortes P, Jesús Mesa R. Characterization of plasmids encoding Extended spectrum β -lactamase and CMY-2 in *Escherichia coli* isolated from animal farms. Int J Antimicrob Agents. 2008; 31: 76- 90.

Cottell J L, Webber M A, Piddock L J V. Persistence of Transferable Extended Spectrum β -Lactamase Resistance in the Absence of Antibiotic Pressure. Antimicrob. Agents Chemother. 2012; 56; 4703–4706.

Cotton M F, Wasserman E, Pieper C H. Invasive disease due to Extended spectrum β -lactamase producing *Klebsiella pneumoniae* in a neonatal unit: the possible role of cockroaches. J Hosp Infect. 2000; 44: 13-17.

Dalela G. Prevalence of Extended spectrum β -lactamase (ESBL) producers among gram negative bacilli from various clinical isolates in a tertiary care hospital at Jhalawar, rajasthan, India. *J Clinical Diagnos Research*. 2012; 6: 182-187.

Dandan He, Partridge S R, Shen J, Zeng Z, Liu L, Rao L, Lv L, Liu A L. CTX-M-123, a Novel Hybrid of the CTX-M-1 and CTX-M-9 Group β -Lactamases Recovered from *Escherichia coli* isolates in China. *Antimicrob Agents Chemother*. 2013; 57: 4068–4071.

Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. *Nature*. 1965; 208: 239-41.

Davies J, Davies D. Origins and Evolution of Antibiotic Resistance. *Microbiol. Mol. Biol. Rev*. 2010, 74: 417-433.

De Gelder L, Ponciano J M, Joyce P, Top E M. Stability of a promiscuous plasmid in different hosts: no guarantee for a long term relationship. *Microbiol*. 2007; 153: 452–463.

Demain A L, Elander R P. The β -lactam antibiotics: past, present, and future. *Antonie Van Leeuwenhoek*. 1999; 75: 5-19.

Dhanji H, Patel R, Wall R, Doumith M, Patel B, Hope R, Livermore D M, Woodford N. Variation in the genetic environments of *bla*_{CTX-M-15} in *Escherichia coli* from the faeces of travellers returning to the United Kingdom. *J Antimicrob Chemother*. 2011; 66, 1005–1012.

Djamdjian L, Naas T, Tande D, Cuzon G, Saliou C H, Nordmann P. CTX-M-93, a CTX-M Variant Lacking Penicillin Hydrolytic Activity. *Antimicrob Agents Chemother*. 2011; 56: 1861–1866.

Dolejskaa M, Brhelova E, Dobiasova H, Krivdova J, Jurankova J, Sevcikova A, Dubskad L, Literaka I, Cizekba A, Vavrina M, Kutnikova L, Sterba J. Dissemination of IncFIIK-type plasmids in multiresistant CTX-M-15 producing *Enterobacteriaceae* isolates from children in hospital paediatric oncology wards. *Inter J Antimicrob Agents* 2012; 40: 510– 515.

Drawz S M, Bonomo R A. Three decades of β -lactamase inhibitory. *Clinical Microbiol Rev.* 2010; 23: 160-201.

Du B, Long Y, Liu H. Extended spectrum β -lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* blood stream infection: risk factors and clinical outcome. *Intensive Care Med.* 2002; 28: 1718-1723.

Du Bois S K, Marriott M S, Amyes S G. *TEM* and *SHV* derived Extended spectrum β -lactamases : relationship between selection, structure and function. *J Antimicrob Chemother* 1995; 35: 7-22.

Dubois V, Poirel L, Marie C, Arpin C, Nordmann P, Quentin C. Molecular characterization of a novel class 1 integron containing *bla*_{GES-1} and a fused product of *aac3-Ib/aac6'-Ib'* gene cassettes in *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 2002; 46: 638–645.

Eckert C, Gautier V, Arlet G. DNA sequence analysis of the genetic environment of various *bla*_{CTX-M} genes. *J Antimicrob. Chemother.* 2006; 57: 14–23.

Ehmann D E, Jahic H, Ross P L, Gu R F, Hu J, Kern G, Walkup K, Fisher S L. Avibactam is a covalent, reversible, non- β -lactam β -lactamase inhibitor. *PNAS.* 2012; 109: 1663–11668.

El-Kholy A, Baseem H, Hall G S, Procop G W, Longworth D L. Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. *J Antimicrob Chemother.* 2003; 51: 625-30.

Ensor V M, Shahid M, Evans J T. Occurrence, prevalence and genetic environment of CTX-M β -lactamases in *Enterobacteriaceae* from Indian hospitals. *J Antimicrob Chemother.* 2006; 58: 1260–1263.

Essack S Y. The development of β -lactam antibiotics in response to the evolution of β -lactamases. *Pharm Res,* 2001; 18: 1391-9.

Fam N, Leflon-Guibout V, Fouad S, Boul-Fad L, Marcon E, Desouky D, El-Defrawy I, Bou-Aitta A, Klena J, Nicolas-Chanoine M H. CTX-M-15 producing *Escherichia coli* clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital setting. *Microb. Drug Resist.* 2011; 17: 67-73.

Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of Extended spectrum β -lactamases among *Escherichia coli* isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. *J Clin Microbiol.* 2008; 46: 707-12.

Fang H, Lundberg C. Molecular epidemiological analysis of *Escherichia coli* isolates producing Extended spectrum β -lactamases for identification of nosocomial outbreaks in Stockholm, Sweden. *J Clin Microbiol.* 2004; 42: 5917-5920.

Feizabadi M M, Yeganeh S M, Mirsalehian A, Azimi P, Mirafshar S M, Mahboobi M, Nili F, Yadegarinia D. Genetic characterization of ESBL producing strains of *Klebsiella pneumoniae* from Tehran hospitals. *J Infect Dev Ctries.* 2010; 4: 609-615.

Fernandez Vazquez M, Munoz Bellido J L, Garcia M I, Rodriguez J A. *Salmonella enterica* serovar *enteritidis* producing a *TEM-52* β -lactamase: first report in Spain. *Diagn Microbiol Infect Dis*. 2006; 55: 245-6.

Flemming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *Br. J Exp Pathol*. 1929; 10: 226–36.

Fonseca E L, Vieira V V, Cipriano R, Vicente A C P. Emergence of *bla*_{GES-5} in clinical colistin-only sensitive (COS) *Pseudomonas aeruginosa* strain in Brazil. *J. Antimicrob. Chemother*. 2007; 59: 576-577.

Ford P J, Avison M B. Evolutionary mapping of the SHV β -lactamase and evidence for two separate IS26 dependent *bla*_{SHV} mobilization events from the *Klebsiella pneumoniae* chromosome. *J. Antimicrob. Chemother*. 2004; 54: 69–75.

Fournier P E, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D, Claverie J M. Comparative genomics of multidrug resistance in *Acinetobacter baumannii*. *Plos Genet*. 2006; 2: 62-72.

Fournier D, Hocquet D, Dehecq B, Cholley P, Plesiat P. Detection of a new Extended-spectrum oxacillinase in *Pseudomonas aeruginosa*. *J Antimicrob Chemother*. 2010; 65: 364-365.

Francia M V, Varsaki A, Barcia P G, Latorre A, Drainas C, Cruz F D. A classification scheme for mobilization regions of bacterial plasmids. *FEMS Microbiol. Rev*. 2004; 28: 79–100.

Freschi C R, Carvalho L F O S, Oliveira C J B. Comparison of DNA extraction methods and selective enrichment broths on the detection of *Salmonella*

typhimurium in swine feces by polymerase chain reaction (PCR). Brazilian J. Microbiol. 2005; 36: 363-367.

Fursova N, Pryamchuk S, Kruglov A, Abaev I, Pecherskikh E, Kartsev N, Svetoch E, Dyatlov I. The Novel *CTX-M-116* β -Lactamase Gene Discovered in *Proteus mirabilis* is Composed of Parts of the *CTX-M-22* and *CTX-M-23* Genes. Antimicrob Agents Chemother. 2013, 57: 1552–1555.

Gaillot O, Maruejols C, Abachin E, Lecuru F, Arlet G, Simonet M, Berche P. Nosocomial outbreak of *Klebsiella pneumoniae* producing *SHV-5* Extended spectrum β -lactamase, originating from a contaminated ultrasonography coupling gel. J. Clin. Microbiol. 1998; 36: 1357–1360.

Garau G, Garcia-Saez I, Bebrone C, Anne C, Mercuri P, Galleni M, Frere J M, Dideberg O. Update of the standard numbering scheme for class B β -lactamases. Antimicrob. Agents Chemother. 2004; 48: 2347-2349.

Georgopapadakou N H, Bertasso A, Chan K K, Chapman J S, Cleeland R, Cummings L M. Mode of action of the dual action cephalosporin Ro 23-9424. Antimicrob. Agents Chemother. 1989; 33: 1067-71.

Georgopapadakou N H, Bertasso A. Mechanisms of action of Cephalosporin 3'-quinolone esters, carbamates and tertiary amines in *E. coli*. Antimicrob. Agents Chemother. 1993; 37: 559-65.

Girlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, Nordmann P. Nosocomial spread of the integron-located *veb-1* like cassette encoding an Extended spectrum β -lactamase in *Pseudomonas aeruginosa* in Thailand. Clin. Infect. Dis. 2002; 34: 603–611.

Girlich D, Poirel L, Nordmann P. Diversity of clavulanic acid inhibited Extended spectrum β -lactamases in *Aeromonas* spp. from the Seine River, Paris, France. *Antimicrob. Agents Chemother.* 2011; 55: 1256–1261.

Girlich D, Poirel L, Nordmann P. *PER-6*, an Extended Spectrum β -Lactamase from *Aeromonas salo saccharophila*. *Antimicrob Agents Chemother.* 2010; 54: 1619–1622.

Giuffre M, Cipolla D, Bonura C, Geraci D M, Aleo A, Noto S D, Nociforo F, Corsello G, Mammina C. Outbreak of colonizations by Extended spectrum β -lactamase-producing *Escherichia coli* sequence type 131 in a neonatal intensive care unit, Italy. *Antimicrobial Resis Infection Control.* 2013, 2: 8.

Godet B O, Salem Y B. Nosocomial outbreak caused by *Salmonella enterica* serotype Livingstone producing CTX-M-27 Extended Spectrum β -lactamase in a neonatal Unit in Sousse, Tunisia. *J Clin Microbiol.* 2005; 43: 1037-1044.

Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for Extended spectrum β -lactamase and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997–2004). *Diag. Microbiol Infect Dis.* 2005; 53: 257–264.

Goren MG, Chmelnitsky I, Carmeli Y, Navon-Venezia S. Plasmid encoded *OXA-48* carbapenemase in *Escherichia coli* from Israel. *J Antimicrob Chemother.* 2011; 66: 672-3.

Govinden U, Mocktar C. *CTX-M-37* in *Salmonella enterica* serotype Isangi from Durban, South Africa. *Int J Antimicrob Chemother.* 2006; 28: 288-91.

Goyal A, Prasad K N, Prasad A, Gupta S, Ghoshal U, Ayyagari A. Extended spectrum β -lactamases in *Escherichia coli* & *Klebsiella pneumoniae* and associated risk factors. *Indian J Med Res* 2009; 129: 695-700.

Greenwood D, Finch R, Davey P, Wilcox M. Antimicrobial Chemotherapy. (5th edition) by Oxford University Press Inc., New York. 2006.

Grobner S, Linke D, Schutz W, Fladerer C, Madlung J, Autenrieth I B, Witte W, Pfeiffer Y. Emergence of carbapenem non susceptible Extended spectrum β -lactamase producing *Klebsiella pneumoniae* isolates at the University Hospital of Tubingen, Germany. J. Med. Microbiol. 2009; 58: 912-922.

Grover S S, Sharma M. Antimicrobial susceptibility pattern and prevalence of Extended spectrum β -lactamase (ESBLs) producing strains of *Klebsiella pneumoniae* from a major hospital in New Delhi. J Commun Dis. 2004; 36: 17-26.

Grover S S., Sharma M, Chattopadhyaya D, Kapoor H, Pasha S T, Singh G. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in *Klebsiella pneumoniae*: Emergence of high resistance against cefepime, the fourth generation cephalosporin. J. Infect. 2006; 53: 279-288.

Gruteke P, Goessens W, Gils J V. Patterns of resistance associated with Integrons, the Extended Spectrum β -lactamase *SHV-5* gene, and a multidrug efflux pump of *Klebsiella pneumoniae* causing a nosocomial outbreak. J Clin Microbiol. 2003; 41: 1161-1166.

Guenther S, Ewers C, Wieler L H. Extended spectrum β -Lactamases producing *E. coli* in Wildlife, yet Another Form of Environmental Pollution? Front. Microbiol. 2011; 2: 246.

Hachler H, Kotsakis S D, Tzouveleki L S, Geser N, Lehner A, Miriagou V, Stephan R. Inter J Antimicrob Agents. 2013; 41: 90-95.

Hadziyannis E, Tuohy M, Thomas L, Procop G W, Washington J A, Hall G S. Screening and confirmatory testing for Extended spectrum β -lactamases

(ESBL) in *Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca* clinical isolates. *Diag. Microbiol. Infect. Dis.* 2000; 36: 113–117.

Hall B G, Barlow M. Revised Ambler classification of β -lactamases. *J Antimicrob Chemother.* 2005; 55: 1050-1051.

Hall R M, Collis C M. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. *Mol. Microbiol.* 1995; 15: 593–600.

Hall, R.M. Collis C M, Kim M J, Partridge S R, Recchia G D, Stokes H W. Mobile gene cassettes and integrons in evolution. *Ann. N. Y. Acad. Sci.* 1999; 870: 68–80.

Hammer D A, Dongol S. High prevalence of Extended spectrum β -lactamase producing Enterobacteriaceae in Nepal. *Int J Antimicrob Agents.* 2007; 30: 471-472.

Hanson N D, Moland E S. Enzymatic characterization of TEM – 63, a TEM – type Extended spectrum β -lactamase expressed in three different genera of *Enterobacteriaceae* from South Africa. *Diagn Microbiol Infect Dis.* 2001; 40: 199-201.

Hansotia J B, Agarwal V. Extended spectrum β -lactamase mediated resistance to third generation cephalosporins in *Klebsiella pneumoniae* from Nagpur, central India. *Indian J Med Res.* 1997; 105: 158-61.

Harajly M, Khairallah M T, Corkill J E, Araj G F, Matar G M. Frequency of conjugative transfer of plasmid encoded *ISEcp1-bla_{CTX-M-15}* and *aac(6')-lb-cr* genes in Enterobacteriaceae at a tertiary care center in Lebanon-role of transferases. *Ann. Clin Microbiol. Antimicrob.* 2010; 9: 19.

Harini L, Ananthan S. Phenotypes of ESBL producing *Klebsiella pneumoniae* and *Escherichia coli* isolates recovered from pediatric subjects in Chennai, southern India. *Inter J Basic and Applied Medical Sciences*. 2012; 2: 126-131.

Hawkey P M. The origins and molecular basis of antibiotic resistance. *B. M. J.* 1998; 317: 657-660.

Hawkey P M. Prevalence and clonality of Extended spectrum β -lactamases in Asia. *Clin Microbiol Infect*. 2008; 14:159-65.

Heimer D, Edberg E. ESBL infection in the neonatal unit at the Central Hospital in Vasteras. *EPI up to date*. 2009; 36: 8.

Helinski D R. Introduction to plasmids: a selective view of their history. *In* 371 B. E. Funnell, and G. J. Philips (ed.), *Plasmid biology*. ASM Press, Washington, DC. 2004: 1-21.

Herindrainy P, Randrianirina F, Ratovoson R, Ratsima Hariniana E, Buisson Y, Genel N. Rectal carriage of Extended spectrum β -lactamase-producing gram negative bacilli in community settings in Madagascar. *Plos One*. 2011; 6:e22738.

Howard C, Daal A V, Kelly J. Identification and minisequencing based discrimination of *SHV* β -lactamases in nosocomial infection associated *Klebsiella pneumoniae* in Brisbane, Australia. *Antimicrob Agents Chemother*. 2002; 46: 659–664.

Humphrey B, Thomson N R, Thomas C M, Brooks K, Sanders M, Delsol A A, Roe J M, Bennett P M, Enne V I. Fitness of *Escherichia coli* strains carrying expressed and partially silent IncN and IncP1 plasmids. *BMC Microbiology*. 2012, 12: 53.

- Huovinen P, Huovinen S, Jacoby G A. Sequence of PSE-2 β -lactamase. *Antimicrob. Agents Chemother.* 1988; 32: 134-136.
- Ishii Y, Kimura S. Extended Spectrum β -lactamase producing shiga toxin gene (*stx₁*) positive *Escherichia coli* O26:H11: a new concern. *J Clin Microbiol.* 2005; 43: 1072–1075.
- Jabeen K, Zafar A, Hasan R. Frequency and sensitivity pattern of Extended spectrum β – lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. *J Pak Med Assoc.* 2005; 55: 436–9.
- Jacoby G A, Medeiros A A, O'Brien T F. Broad spectrum transmissible β -lactamases. *N Engl J Med.* 1988 ; 319 : 723–724.
- Jacoby G A, Price L S M. The New β -Lactamases. *N Engl J Med.* 2005; 352: 380-91.
- Jacoby G A. AmpC β -lactamases. *Clin. Microbiol. Rev.* 2009; 22: 161–182.
- Jacoby G A. *History of Drug Resistant Microbes.* Burlington: Human press Springer Science; 2009.
- Jacoby J A, Archer G L. New mechanisms of bacterial resistance to antimicrobial agents. *N Engl J Med.* 1991; 324: 601-612.
- Jain A, Roy I, Gupta M K. Prevalence of Extended spectrum β -lactamase producing Gram negative bacteria in septicemic neonates in a tertiary care hospital. *J Med Microbiol.* 2003; 52: 421–5.
- Jamie K, Whitney D. Ceftobiprole, a Broad Spectrum Cephalosporin with Activity against Methicillin-Resistant *Staphylococcus aureus* (MRSA); *Drug Forecast;* 2008; 33: 631-641.

Jiang X, Ni Y, Jiang Y, Yuan F, Han L, Li M, Liu H, Yang L, Lu Y. Outbreak of Infection Caused by *Enterobacter cloacae* producing the Novel VEB-3 β -Lactamase in China. J. Clin Microbiol. 2005; 43: 826–831.

Joseph B L. Ceftaroline fosamil: a new broad spectrum cephalosporin. J Antimicrob Chemother 2011; 66: 11–18.

Jouini A, Vinue L. Characterization of CTX -M and SHV Extended spectrum β – lactamases and associated resistance genes in *Escherichia coli* strains of food samples in Tunisia. J Antimicrob Chemother. 2007; 60: 1137–41.

Juan C, Mulet X, Zamorano L, Albert S, Perez J L, Oliver A. Detection of the Novel Extended spectrum β -Lactamase OXA-161 from a Plasmid Located Integron in *Pseudomonas aeruginosa* Clinical Isolates from Spain. Antimicrob. Agents Chemother. 2009; 53: 5288–5290.

Kanj S S, Corkill J E, Kanafani Z A, Araj G F, Hart C A, Jaafar R, Matar G M. Molecular characterization of Extended spectrum β -lactamase producing *Escherichia coli* and *Klebsiella* spp. isolates at a tertiary care centre in Lebanon. Clin. Microbiol. Infect 2008; 14:501-504.

Karami N, Helldal L, Olsson C W, Ahren C, Edward R. B. M. Sub-Typing of Extended-Spectrum β -Lactamase Producing Isolates from a Nosocomial Outbreak: Application of a 10-Loci Generic *Escherichia coli* Multi Locus Variable Number Tandem Repeat Analysis. Plos One. 2013; 8: e83030.

Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid mediated extended spectrum β -lactamase (CTX – M – 3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett. 2001; 201: 237 – 41.

Kariuki S, Corkill J E, Revathi G. Molecular characterization of a novel plasmid encoded cefotaximase (CTX–M–12) found in clinical *Klebsiella*

pneumoniae isolates from Kenya. Antimicrob agents Chemother. 2001; 45: 2141–2143.

Khanfar H S, Bindayna K M, Senok A C, Botta G A. Extended spectrum β -lactamases (ESBL) in *Escherichia coli* and *Klebsiella pneumoniae*: trends in the hospital and community settings. J Infect Dev Ctries. 2009; 3: 295-9.

Kizirgil A, Demirdag K, Ozden M, Bulut Y, Yakupogullari Y, Toraman Z A. In vitro activity of three different antimicrobial agents against ESBL producing *Escherichia coli* and *Klebsiella pneumoniae* blood isolates. Microbiol Res. 2005; 160: 135-40.

Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. Infection. 1983; 11: 315-317.

Koeleman J G M, Stoof J, Der bijl M W V, Vandenbroucke grauls C M J E, Savelkoul P H M. Identification of Epidemic Strains of *Acinetobacter baumannii* by Integrase Gene PCR. J Clin. Microbiol. 2001; 39: 8-13.

Kong K F, Schneper L, Mathee K. β -lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS. 2009; 118; 1–36.

Kotsakis S D, Papagiannitsis C C, Tzelepi E, Legakis N J, Miriagou V, Tzouvelekis L S. GES-13, a β -Lactamase Variant Possessing Lys-104 and Asn-170 in *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 2010; 54: 1331–1333.

Krisztina M. Papp W, Endimiani A, Taracila M A, Bonomo R A. Carbapenems: Past, Present, and Future. Antimicrob. Agents Chemother. 2011; 55: 4943–4960.

Kruger T, Szabo D, Keddy K H. Infections with non typhoidal *Salmonella* species producing *TEM-63* or a novel TEM enzyme, *TEM-131* in South Africa. *Antimicrob. Agents Chemother.* 2004; 48: 4263–70.

Kwan SooKo, Joon-Sup Yeom, Mi Young Lee, Kyong Ran Peck, Jae-Hoon Song. Clonal Dissemination of Extended Spectrum β -Lactamase (ESBL) Producing *Klebsiella pneumoniae* Isolates in a Korean Hospital. *J Korean Med Sci.* 2008; 23: 53-60.

Lal P, Kapil A. Occurrence of TEM & SHV gene in Extended spectrum β -lactamase producing *Klebsiella* sp. isolated from a tertiary care hospital. *Indian J Med Res.* 2007; 125: 173–178.

Lartigue M D, Poirel L, Aubert D, Nordmann P. In Vitro Analysis of *ISEcp1B*-Mediated Mobilization of Naturally Occurring β -Lactamase Gene *bla_{CTX-M}* of *Kluyvera ascorbata*. *Antimicrob. Agents Chemother.* 2006; 50: 1282–1286.

Lartigue M F, Poirel L, Nordmann P. Diversity of genetic environment of *bla_{CTX-M}* genes. *FEMS Microbiol. Letters.* 2004; 234: 201-207.

Lavigne J P, Bouziges N, Chanal C. Molecular epidemiology of *Enterobacteriaceae* isolates producing Extended Spectrum β -lactamases in a French Hospital. *J Clin Microbiol.* 2004; 42: 3805–3808.

Laxminarayan H, Sourirajan A. Phenotypes of ESBL-producing *Klebsiella pneumoniae* and *Escherichia coli* isolates recovered from pediatric subjects in Chennai, southern India. *Inter J Basic and Applied Medical Sciences.* 2012; 2: 126-131.

Lee M Y, Ko K S, Kang C I, Chung D R, Peck K R, Song J H. High prevalence of CTX-M-15-producing *Klebsiella pneumoniae* isolates in Asian

countries: diverse clones and clonal dissemination. *Inter J Antimicrob Agents*. 2011; 38: 160–163.

Lee S, Park Y J, Kim M, Lee H K, Han K, Kang C S. Prevalence of Ambler class A and D β -lactamases among clinical isolates of *Pseudomonas aeruginosa* in Korea. *J Antimicrob. Chemother.* 2005; 56: 122-127.

Leflon G V, Jurand C, Bonacorsi S, Espinasse F, Guelfi M C, Duportail F, Heym B, Bingen E, NicolasChanoine M H. Emergence and spread of three clonally related virulent isolates of CTX-M-15-producing *Escherichia coli* with variable resistance to aminoglycosides and tetracycline in a Frenchgeriatric hospital. *Antimicrob. Agents Chemother.* 2004; 48: 3736-3742.

Leon G, Roy P H. Excision and integration of cassettes by an integron integrase of *Nitrosomonas europaea*. *J. Bacteriol.* 2003; 185: 2036–2041.

Levesque C, Piche L, Larose C, Roy P H. PCR mapping of integrons reveals several novel combinations of resistance genes. *Antimicrob. Agents Chemother.* 1995; 39: 185-191.

Li B, Hu Y, Wang Q, Yi Y, Woo PCY, Jing H, Zhu B, Liu C H. Structural Diversity of Class 1 Integrons and Their Associated Gene Cassettes in *Klebsiella pneumoniae* Isolates from a Hospital in China. *Plos One*. 2013; 8: 1-9.

Li C R, Li Y. Dissemination and spread of Extended spectrum β -lactamases among clinical isolates of *Klebsiella pneumoniae* in central China. *Int J Antimicrob Agents*. 2003; 22: 521–525.

Lim K T, Yasin R, Yeo C C, Puthuchery S, Thong K L. Characterization of Multidrug Resistant ESBL Producing *Escherichia coli* Isolates from Hospitals in Malaysia. *J Biomedicine Biotechnol.* 2009; 2009: 165637.

Linkevicius M, Sandegren L, Andersson D I. Mechanisms and fitness costs of tigecycline resistance in *Escherichia coli*. J Antimicrob Chemother. 2013; 68: 2809-2819.

Livermore D M. Defining an Extended spectrum β -lactamase. Clin.Microbiol. Infect. 2008; 14: 3-10.

Livermore D M. β -Lactamases in Laboratory and Clinical Resistance. Clin Microbiol Rev. 1995; 8: 557–584.

Lowe M N, Lamb H M. Meropenem An Updated Review of its Use in the Management of Intra Abdominal Infections. Drugs. 2000; 60; 619-646.

Luvsansharav UO, Hirai I, Nakata A, Imura K, Yamauchi K, Niki M. Prevalence of and risk factors associated with faecal carriage of CTX-M β -lactamase producing Enterobacteriaceae in rural Thai communities. J Antimicrob Chemother. 2012; 18.

Lytsy B, Sandegren L, Tano E, Torell E, Andersson D I, Melhus A. The first major Extended spectrum β -lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant *Klebsiella pneumoniae* producing CTX-M-15. APMIS. 2008; 116: 302-8.

M'Zali F H, Heritage J, Gascoyne-Binzi D M, Snelling A M, Hawkey P M. PCR single strand conformational polymorphism can be used to detect the gene encoding SHV-7 Extended spectrum β -lactamase and to identify different SHV genes within the same strain. J. Antimicrob. Chemother. 1998; 41: 123–125.

Mabilat C, Courvalin P. Development of “oligotyping” for characterization and molecular epidemiology of TEM β -lactamases in members of the family *Enterobacteriaceae*. Antimicrob. Agents Chemother. 1990; 34: 2210–2216.

- Machado E, Canton R, Baquero F, Galan J C, Rollan A, Peixe L, Coque T M. Integron content of Extended Spectrum β -Lactamase Producing *Escherichia coli* Strains over 12 Years in a Single Hospital in Madrid, Spain. *Antimicrob. Agents Chemother.* 2005; 49: 1823–1829.
- Machado E, Ferreira J, Novais A, Peixe L, Cantón R, Baquero F, Coque T M. Preservation of integron types among Enterobacteriaceae producing Extended spectrum β -lactamases in a Spanish hospital over a 15-year period (1988 to 2003). *Antimicrob Agents Chemother.* 2007; 51: 2201-2204.
- Mahillon J, Leonard C, Chandler M. IS elements as constituents of bacterial genomes. *Res Microbiol.* 1999; 150: 675–687.
- Mahrouki S, Belhadj O, Chihi H, Mohamed B M, Celenza G, Amicosante G, Perilli M. Chromosomal *bla*_{CTX-M-15} associated with ISEcp1 in *Proteus mirabilis* and *Morganella morganii* isolated at the military hospital of Tunis, Tunisia. *J. Med. Microbiol.* 2012; 61: 1286-1289.
- Manoharan A, Premalatha K, Chatterjee S, Mathai D, SARI Study Group. Correlation of *TEM*, *SHV* and *CTX-M* Extended spectrum β -lactamases among Enterobacteriaceae with their in vitro antimicrobial susceptibility. *Indian J Medical Microbiol.* 2011; 29: 161-164.
- Mantengoli E, Rossolini G M. Tn5393d, a complex Tn5393 derivative carrying the *PER-1* Extended spectrum β -lactamase gene and other resistance determinants. *Antimicrob. Agents Chemother.* 2005; 49: 3289–3296.
- Manzur A, Tubau F, Pujol M, Calatayud L, Dominguez M L, Pena C, Sora M, Gudiol F, Ariza J. Nosocomial Outbreak Due to Extended Spectrum β -Lactamase Producing *Enterobacter cloacae* in a Cardiothoracic Intensive Care Unit. *J Clin Microbiol.* 2007; 45: 2365–2369.

Marchiaro P, Ballerini V, Spalding T, Cera G, Mussi M A, Moran Barrio J, Vila A J, Viale A M, Limansky A S. A convenient microbiological assay employing cell free extracts for the rapid characterization of Gram negative carbapenemase producers. *J. Antimicrob. Chemother.* 2008; 62: 336–344.

Marquez C, Labbate M, Raymondo C, Fernandez J, Gestal A M, Holley M, Borthagaray G, Stokes H W. Urinary Tract Infections in a South American Population: Dynamic Spread of Class 1 Integrons and Multidrug Resistance by Homologous and Site Specific Recombination. *J Clin Microbiol.* 2008; 46: 3417–3425.

Marty L, Jarlier V. Surveillance of multiresistant bacteria: justification, role of the laboratory, indicators, and recent French data. *Pathol Biol (Paris).* 1998; 46: 217–226.

Maurya A P, Talukdar A D, Chanda D D, Chakravarty A, Bhattacharjee A. Integron borne expansion of VEB-1 Extended spectrum β lactamase in *Pseudomonas aeruginosa* in a tertiary care hospital of India. *Antimicrob Agents Chemother.* 2014; 58: 6966-6969.

Mazel D. Integrons: agents of bacterial evolution. *Nature Rev Microbiol.* 2006; 4: 608-620.

Milazzo G, Blandino F C, Musumeci R, Nicoletti G, Speciale A. Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. *J Antimicrob Chemother.* 2003; 51: 721–725.

Mims C, Goering R V, Dockrell H M, Zuckerman M, Wakelin D, Roitt I M, Chiodini P L, *Medical Microbiology.* 2008.

Miranda G, Castro N. Clonal and horizontal dissemination of *Klebsiella pneumoniae* expressing SHV-5 Extended Spectrum β -Lactamase in a Mexican pediatric hospital. J Clin Microbiol. 2004; 42: 30-35.

Mitsuhashi S, Inoue M. Mechanisms of resistance to β lactam antibiotics. In S. Mitsuhashi (ed.), β -lactam antibiotics. Springer-Verlag, New York. 1981: 41–56.

Modi R I, Adams J. Coevolution in bacteria plasmid populations. Evolution. 1991; 45: 656–67.

Moland E S, Sanders C C, Thomson K S. Occurrence of newer β -lactamases in *Klebsiella pneumoniae* isolates from 24 U. S. hospitals. Antimicrob Agents Chemother. 2002; 46: 3837–3842.

Moland E S, Sanders C C, Thomson K S. Can. Results obtained with commercially available MicroScan microdilution panels serve as an indicator of β -lactamase production among *Escherichia coli* and *Klebsiella* isolates with hidden resistance to Expanded spectrum cephalosporins and aztreonam? J. Clin. Microbiol. 1998; 36: 2575–2579.

Moosdeen F, Williams J D, Yamabe S. Antibacterial characteristics of YTR 830, a sulfone β -lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob Agents Chemother. 1988; 32: 925-927.

Moubareck C, Bremont S, Conroy M C, Courvalin P, Lambert T. *GES-11*, a novel integron-associated *GES* variant in *Acinetobacter baumannii*. Antimicrob. Agents Chemother. 2009; 53: 3579–3581.

Mshana S E, Imirzalioglu C, Hossain H, Hain T, Domann E, Chakraborty T. Conjugative IncFI plasmids carrying *CTX-M-15* among *Escherichia coli*

ESBL producing isolates at a University Hospital in Germany. *BMC. Infect. Dis.* 2009; 9: 97.

Mshana S E, Kamugisha E, Mirambo M, Chakraborty T, Lyamuya E F. Prevalence of multiresistant gram negative organisms in a tertiary hospital in Mwanza, Tanzania. *BMC Res Notes.* 2009; 2: 49.

Mulgrave L, Attwood P V. Characterization of an *SHV-5* related broad spectrum β -lactamase in *Enterobacteriaceae* from Western Australia. *Pathology.* 1993; 25: 71–75.

Mulgrave L. Extended broad spectrum β -lactamases in Australia. *Med J Aust.* 1990; 152: 444–445.

Mulvey M R, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, Simor A E, Paton S. Canadian Hospital Epidemiology Committee, Canadian Nosocomial Infection Surveillance Program, Health Canada, 2004.

Mushtaq S, Hope R, Warner M, Livermore D M. Activity of faropenem against cephalosporin resistant *Enterobacteriaceae*. *J Antimicrob. Chemother.* 2007; 59: 1025–1030.

Musoke R N, Revathi G. Emergence of multidrug resistant gram negative organisms in a neonatal unit and the therapeutic implications. *J Trop Pediatr.* 2000; 46: 86–91.

Naas T, Mikami Y, Imai T, Poirel L, Nordmann P. Characterization of In53, a class 1 plasmid and composite transposon located integron of *Escherichia coli* which carries an unusual array of gene cassettes. *J. Bacteriol.* 2001; 183: 235–249.

Naas T, Namdari F, Reglier-Poupet H, Poyart C, Nordmann P. Panresistant Extended-spectrum β -lactamase SHV-5 producing *Acinetobacter baumannii* from New York City. J. Antimicrob. Chemother. 2007; 60: 1174–1176.

Naas T, Poirel L, Nordmann P. Minor Extended spectrum β -lactamases. Clin. Microbiol. Infect. 2008; 14: 42–52.

Nagano N, Nagano Y, Cordevant C, Shibata N, Arakawa Y. Nosocomial transmission of CTX-M-2 β -lactamase-producing *Acinetobacter baumannii* in a neurosurgery ward. J. Clin. Microbiol. 2004; 42: 3978–3984.

Nagano N, Nagano Y. Nosocomial transmission of CTX-M-2 β -lactamase producing *Acinetobacter baumannii* in a neurosurgery ward. J Clin Microbiol. 2004a; 42: 3978 – 3984.

Naseer U, Sundsfjord A. The CTX-M conundrum: dissemination of plasmids and *Escherichia coli* clones. Microb. Drug Resist. 2011; 17: 83-97.

Nass T, Nordmann P. OXA type β -lactamses. Current Pharma Diseases. 1999; 5: 865-879.

Nathisuwan S, Burgess DS, Lewis II J S. ESBLs: Epidemiology, detection and treatment. Pharmacotherapy. 2001; 21: 920-928.

Ndugulile F, Jureen R. Extended spectrum β -lactamases among gram negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. B M C Infect Dis. 2005; 15: 86.

Nemoy L L, Kotetishvili M, Tigno J, Keefer-Norris A, Harris A D, Perencevich E N, Johnson J A, Torpey D, Sulakvelidze A, Morris J G, Stine O C. Multilocus Sequence Typing versus Pulsed Field Gel Electrophoresis for

Characterization of Extended Spectrum β -Lactamase Producing *Escherichia coli* Isolates. J Clin Microbiol. 2005; 1776–1781.

Nijssen S, Florijn A, Bonten M J M, Schmitz F J, Verhoef J, Fluit A C. β -lactam susceptibilities and prevalence of ESBL producing isolates among more than 5000 European Enterobacteriaceae isolates. Inter J Antimicrobial Agents. 2004; 24: 585–591.

Nordmann P, Guibert M. Extended spectrum β -lactamases in *Pseudomonas aeruginosa*. J. Antimicrob. Chemother. 1998. 42:128-131.

Nordmann P, Mammeri H. Extended spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007; 2: 297–307.

Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. Characterization of a novel Extended spectrum β -lactamase from *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 1993; 37: 962–969.

Normark B H, Normark S. Evolution and spread of antibiotic resistance. J. Intern. Med. 2002; 252: 91-106.

Novais A, Canton R. Emergence and dissemination of *Enterobacteriaceae* isolates producing CTX–M–1 Like enzymes in Spain are associated with IncFII (CTX–M–15) and broad host range (CTX–M–1, - 3 and - 32) plasmids. Antimicrob Agents Chemother. 2007; 51: 796 – 799.

Novais A, Viana D, Baquero F, Martínez-Botas J, Canton R, Coque T M. Contribution of IncFII and Broad-Host IncA/C and IncN Plasmids to the Local Expansion and Diversification of Phylogroup B2 *Escherichia coli* ST131 Clones Carrying *bla*_{CTX-M-15} and *qnrS1* Genes. Antimicrob. Agents Chemother. 2012; 56: 2763–2766.

Nuesch-Inderbinnen M T, Hachler F H K H. Detection of genes coding for Extended spectrum SHV β -lactamases in clinical isolates by a molecular genetic method, and comparison with the Etest. *Eur. J. Clin. Microbiol. Infect. Dis.* 1996; 15: 398–402.

Okeke, I. N. and Edelman, R. Dissemination of antibiotic resistant bacteria across geographic borders. *Clin Infect Dis.* 2001; 3: 364-369.

Oliver A, Coque T M, Alonso D, Valverde A, Baquero F, Canton R. CTX-M-10 linked to a phage related element is widely disseminated among *Enterobacteriaceae* in a Spanish hospital. *Antimicrob. Agents Chemother.* 2005; 49: 1567–1571.

Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of *Escherichia coli* in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). *J. Antimicrob. Chemother.* 2002; 50: 945-952.

Otman J, Cavassin E D. An outbreak of Extended spectrum β -lactamase producing *Klebsiella* spp. in a neonatal intensive care unit in Brazil. *Infect Control Hosp Epidemiol.* 2002; 23: 8–9.

Ouellette M, Paul G C, Philippon A M, Roy P H. Oligonucleotide probes (TEM-1, OXA-1) versus isoelectric focusing in β -lactamase characterization of 114 resistant strains. *Antimicrob. Agents Chemother.* 1988; 32: 397–399.

Pai H, Kim M R. A nosocomial outbreak of *Escherichia coli* producing CTX–M–15 and OXA–30 β -lactamase. *Infect Cont Hosp Ep.* 2006; 27: 312 – 314.

Partridge S R, Hall R M. Evolution of transposons containing *bla*_{TEM} genes. *Antimicrob. Agents Chemother.* 2005; 49: 1267–1268.

Partridge S R. Analysis of antibiotic resistance regions in Gram-negative bacteria. *FEMS Microbiol. Rev.* 2011; 35: 820–855.

Pasteran F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, Vazquez M, Procopio, A, Tokumoto M, Cagnoni V. Emergence of *PER-2* and *VEB-1a* in *Acinetobacter baumannii* strains in the Americas. *Antimicrob. Agents Chemother.* 2006; 50: 3222–3224.

Paterson D L, Bonomo R A. Extended spectrum β -lactamases: A clinical update. *Clin. Microbiol. Rev.* 2005; 18: 657- 686.

Pellecchi L, Bartoloni A, Fiorelli C. Rapid dissemination and diversity of CTX–M Extended spectrum β -lactamase genes in commensal *Escherichia coli* isolates from Healthy children from low resource settings in Latin America. *Antimicrob Agents Chemother.* 2007; 51: 2720-2725.

Perilli M, Celenza G. Biochemical analysis of TEM–134, a new TEM type Extended spectrum β -lactamase variant produced in a *Citrobacter koseri* clinical isolate from an Italian hospital. *J Antimicrob Chemother.* 2007; 60: 877–880.

Perilli M, Santis F D. Spread of Enterobacteriaceae carrying the *PER-1* Extended spectrum β -lactamase gene as a chromosomal insert: a report from Italy. *J Antimicrob Chemother.* 2007; 59: 323 – 324.

Perilli M, Segatore B, Mugnaioli C, Celenza G, Rossolini G M, Stefani S. Persistence of TEM-52/TEM-92 and SHV-12 Extended spectrum β -lactamases in clinical isolates of Enterobacteriaceae in Italy. *Microb Drug Resist.* 2011; 17: 521-4.

Petersen A, Aarestrup F M, Olsen J E. The invitro fitness cost of antimicrobial resistance in *Escherichia coli* varies with the growth conditions. FEMS Microbiol Lett. 2009; 299: 53–59.

Pfaller M A, Jones R N. Multicenter evaluation of antimicrobial resistance to six broad spectrum β -lactams in Venezuela: comparison of data from 1997 and 1998 using the E test method. Venezuelan antimicrobial Resistance study group. Diagn Microbiol Infect Dis. 1999; 35: 153-158.

Philippon A, Arlet G, Jacoby G A. Plasmid determined AmpC type β -lactamases Antimicrob. Agents Chemother. 2002, 46: 1-11.

Phongpaichit S, Tunyapanit W, Pruekprasert. Antimicrobial resistance, class 1 integron and Extended spectrum β -lactamase in *E. coli* clinical isolates from patients in Sotuh Thailanad. J. Heath Science. 2011; 57: 281-288.

Pitout J D, Church D L. Molecular epidemiology of CTX–M producing *Escherichia coli* in the Calgary Healthy region: Emergence of CTX–M–15 producing isolates. Antimicrob Agents Chemother. 2007; 51: 1281–1286.

Pitout J D, Gregson D B. Community wide outbreaks of clonally related CTX-M-14 β -lactamase producing *Escherichia coli* strains in the Calgary health region. J Clin Microbiol. 2005; 43: 2844–2849.

Pitout J D, Sanders C C, Sanders W E. Antimicrobial resistance with focus on β -lactam resistance in gram-negative bacilli. American J Med. 1997; 103: 51-9.

Pitout J D, Thomson K S, Hanson N D. β -lactamases responsible for resistance to Extended spectrum cephalosporins in *Klebsiella pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* isolates recovered from in South Africa. Antimicrob Agents Chemother. 1998; 42: 1350–1354.

Poirel L, Potron A, Cuesta C D L, Cleary T, Nordmann P, Price L S M. Wild Coastline Birds as Reservoirs of Broad Spectrum β -Lactamase Producing *Enterobacteriaceae* in Miami Beach, Florida. *Antimicrob Agents Chemother.* 2012; 56: 2756–2758.

Poirel L, Bonnin R A, Nordmann P. Genetic support and diversity of acquired Extended spectrum β -lactamases in Gram-negative rods. *Infection, Genetics and Evolution.* 2012a; 12: 883–893.

Poirel L, Cabanne L, Nordmann P. Genetic environment and expression of the Extended spectrum β -lactamase *bla*_{PER-1} gene in Gram-negatives. *Antimicrob. Agents Chemother.* 2005; 49: 1708–1713.

Poirel L, Carattoli A, Bernabeu S, Bruderer T, Frei R, Nordmann P. A novel IncQ plasmid type harbouring a class 3 integron from *Escherichia coli*. *J. Antimicrob. Chemother.* 2010a; 65: 1594–1598.

Poirel L, Carrer A, Pitout J D, Nordmann P. Integron mobilization unit as a source of mobility of antibiotic resistance genes. *Antimicrob. Agents Chemother.* 2010b; 53: 2492–2498.

Poirel L, Decousser J W, Nordmann P. Insertion sequence ISE_{cp1B} is involved in expression and mobilization of a *bla*_{CTX-M} β -lactamase gene. *Antimicrob. Agents Chemother.* 2003; 47: 2938–2945.

Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of Oxacillinase Mediated Resistance to Imipenem in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 2004; 48: 15-22.

Poirel L, Karim A, Mercat A, Le Thomas I, Vahaboglu H, Richard C, Nordmann P. Extended spectrum β -lactamase producing strain of

Acinetobacter baumannii isolated from a patient in France. J. Antimicrob. Chemother. 1999; 43: 157–158.

Poirel L, Villa L, Bertani A, Pitout J D, Nordmann P, Carattoli A. Expanded spectrum β -lactamase and plasmid mediated quinolone resistance. Emerg. Infect. Dis. 2007; 13: 803-805.

Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A Extended spectrum β -lactamase, and the class 1 integron In52 from *Klebsiella pneumoniae*. Antimicrob. Agents Chemother. 2000; 44: 622–632.

Poirel L, Naas T, Nordmann P. Diversity, Epidemiology, and Genetics of Class D β -lactamases. Antimicrob. Agents Chemother. 2010; 54: 24-38.

Poirel L, Potron A, Cuesta C D L, Cleary T, Nordmann P, Price L S M. Wild Coastline Birds as Reservoirs of Broad Spectrum β -Lactamase Producing *Enterobacteriaceae* in Miami Beach, Florida. Antimicrob. Agents Chemother. 2012b; 56: 2756–2758.

Poirel L, Weldaghen G F. GES-2, a class A β -lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 2002; 49: 561–565.

Poirel L, Weldhagen G F, Naas T, De Champs C, Dove M G, Nordmann P. GES-2, a class A β -lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 2001; 45: 2598–2603.

Pokharel B M, Koirala J, Dahal R K, Mishra S K. Multidrug resistant and Extended spectrum β -lactamase (ESBL) producing *Salmonella enterica* (serotype Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of

resistance and search for newer alternatives. *Int J Infect Dis.* 2006; 10: 434 – 438.

Politi L, Tassios P T, Lambiri A. Repeated Occurrence of Diverse Extended Spectrum β -lactamases in minor food borne *Salmonella enterica* subsp. *Enterica*. *J Clin Microbiol.* 2005; 43: 3453-3456.

Ponnusamykonar P, Vidhya N, Murugan S. Antimicrobial Susceptibility Pattern of ESBL and Non-ESBL Producing Uropathogenic *Escherichia coli* (UPEC) and Their Correlation with Biofilm Formation. *Inter J. MicrobiolRes.* 2013; 4: 56-63.

Poole K. Resistance to β -lactam antibiotics. *Cell Mol Life Sci.* 2004; 61: 2200-23.

Porto A, Ayala J, Gutkind G, Conza J D. A novel OXA-10 like β -lactamase is present in different Enterobacteriaceae. *Diagnos. Microbiol. Infect. Dis.* 2010; 66: 228–229.

Potron A, Poirel L, Croize J, Chanteperdrix V, Nordmann P. Genetic and biochemical characterization of the first Extended spectrum CARB-type β -lactamase, RTG-4, from *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 2009; 53: 3010–3016.

Preston K E, Venezia R A, Stellrecht K A. The SHV-5 Extended spectrum β -lactamase gene of pACM1 is located on the remnant of a compound transposon. *Plasmid* 2004; 51: 48–53.

Qamsari M M, Panah M A, Eftekhari F, Feizabadi M M. Integron mediated multidrug resistance in Extended spectrum β -lactamase producing clinical isolates of *Klebsiella pneumoniae*. *Braz. J. Microbiol.* 2013; 44: 849-854.

Qing Y, Cao K Y, Fang Z L, Huang Y M, Zhang X F, Tian G B, Huang X. Outbreak of PER-1 and diversity of β -lactamases among ceftazidime resistant *Pseudomonas aeruginosa* clinical isolates. J. Med. Microbiol. 2014; 63: 386-392.

Queenan A M, Bush K. Carbapenemases: the versatile β -lactamases. Clin. Microbiol. Rev. 2007; 20:440-458.

Queenan A M, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and β -lactamase activity in AmpC and Extended spectrum β -lactamase (ESBL) producing *Escherichia coli* and *Klebsiella pneumoniae* clinical isolates tested by using NCCLS ESBL methodology. J. Clin. Microbiol. 2004; 42: 269-275.

Quinn J P, Miyashiro D. Novel plasmid mediated β -lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of *Klebsiella pneumoniae*. Antimicrob. Agents Chemother. 1989; 33: 1451-1456.

Radice M, Power J. Early dissemination of CTX-M derived enzymes in South America. Antimicrob. Agents Chemother. 2002; 46: 602-604.

Rahman M M, Haq J A. Prevalence of Extended spectrum β -lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* in an urban hospital in Dhaka, Bangladesh. Int. J Antimicrob. Agents 2004; 24: 508-510.

Ramesh N, Sumathi C S. Urinary tract infection and antimicrobial susceptibility pattern of Extended spectrum β -Lactamase producing clinical isolates. Advan. Biol. Res. 2008; 2: 78-82.

Randall L P, Clouting C, Horton R A, Coldham N G, Wu G, Clifton-Hadley F A, Davies R H, Teale C J. Prevalence of *Escherichia coli* carrying Extended spectrum β -lactamases (CTX-M and TEM-52) from broiler chickens and

turkeys in Great Britain between 2006 and 2009. J. Antimicrob. Chemother. 2010; 1; 86-95.

Ranellou K, Kadlec K, Poulou A, Voulgari E, Vrioni G, Schwarz S, Tsakris A. Detection of *Pseudomonas aeruginosa* isolates of the international clonal complex 11 carrying the *bla*_{PER-1} Extended spectrum β -lactamase gene in Greece. J. Antimicrob. Chemother. 2012; 67: 357-361.

Rasheed J K, Anderson G J, Yigit H, Queenan A M, Domenech-Sanchez A, Swenson J M, Biddle J W, Ferraro M J, Jacoby G A, Tenover F C. Characterization of the Extended-spectrum β -lactamase reference strain, *Klebsiella pneumoniae* K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob. Agents Chemother. 2000; 44: 2382–2388.

Rastogi V, Nirwan P S, Jain S, Kapil A. Nosocomial outbreak of septicemia in neonatal intensive care unit due to Extended spectrum β -lactamase producing *Klebsiella pneumoniae* showing multiple mechanisms of drug resistance. Indian J. Med. Microbiol. 2010; 28: 380-4.

Rath S, Dubey D, Sahu M C, Padhy R N. Surveillance of ESBL producing multidrug resistant *Escherichia coli* in a teaching hospital in India. Asian Pac J Trop Dis. 2014; 4: 140-149.

Raut S S, Surpam R B. Prevalence of *Klebsiella* Spp. & *E. coli*. Indian Med Gazette. 2005: 108-110.

Rezaee M A, Langarizadeh N, Aghazadeh M. First Report of Class 1 and Class 2 Integrons in Multidrug Resistant *Klebsiella pneumoniae* Isolates from Northwest Iran. Jpn. J. Infect. Dis. 2012; 65: 256-259.

Richmond M H, Sykes R B. The β -lactamases of gram negative bacteria and their possible physiological role. Adv. Microb. Physiol. 1973; 9:31–88.

- Robin F, Delmas J, Brebion A, Dubois D, Constantin J M, Bonnet R. TEM-158 (CMT-9), a new member of the CMT-type Extended-spectrum β -lactamases. *Antimicrob. Agents Chemother.* 2007; 51: 4181–4183.
- Robin F, Delmas J, Chanal C, Sirot D, Sirot J, Bonnet R. TEM-109 (CMT-5), a natural complex mutant of TEM-1 β -lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5). *Antimicrob. Agents Chemother.* 2005; 49: 4443–4447.
- Rodloff A C, Goldstein E J C, Torres A. Two decades of imipenem therapy. *J. Antimicrob. Chemother.* 2006; 58: 916–929.
- Rodrigues C, Joshi P. Detection of β -lactamases in nosocomial gram negative clinical isolates. *Indian J Med Microbiol.* 2004; 22: 347-350.
- Rodriguez I, Thomas K, Essen A V, Schink A K, Day M, Chattaway M, Wu G, Mevius D, Helmuth R, Guerra B. Chromosomal location of *bla*_{CTX-M} genes in clinical isolates of *E. coli* from Germany, The Netherlands and the U K. *Inter. J. Antimicrob. Agents.* 2014; 43: 553-557.
- Rodriguez-Bano J, Navarro M D. Epidemiology and clinical features of infections caused by Extended Spectrum β -lactamase producing *Escherichia coli* in non hospitalized patients. *J Clin Microbiol.* 2004; 42: 1089-1094.
- Rojas A R, Beltran J R, Blazquez J. Antibiotics and antibiotic resistance : A bitter fight against evolution. *Inter. J. Medical Microbiol.* 2013; 303: 293-297.
- Rossi F, Garcia P, Ronzon B, Curcio D, Dowzicky M J. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylicline tigecycline and of other antibiotics. *Braz J Infect Dis.* 2008; 12: 405-15.

- Rossolini G M, D'Andrea M M, Mugnaioli C. The spread of CTX-M type Extended spectrum β -lactamases. *Clin. Microbiol. Infect.* 2008; 14: 33–41.
- Roy C, Foz A, Segura C, Tirado M, Fuster C, Reig R. Plasmid determined β -lactamases identified in a group of 204 ampicillin resistant *Enterobacteriaceae*. *J. Antimicrob. Chemother.* 1983; 12: 507–510.
- Royle J, Halasz G. Outbreak of Extended spectrum β -lactamase producing *Klebsiella pneumoniae* in a neonatal unit. *Arch Dis Child Fetal Neonatal Ed.* 1999; 80: 64-68.
- Rudresh S M, Nagarathnamma T. Extended spectrum β -lactamase producing *Enterobacteriaceae* & antibiotic co-resistance. *Indian J Med Res.* 2011; 133: 116–118.
- Sader H S, Gales A C, Granacher T D. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997–98). *Braz J Infect Dis.* 2000; 4: 245-254.
- Sambrook J and Russel D W. *Molecular cloning: A laboratory Manual* (3rd Edition), Volume III. Press: Cold spring Harbor Laboratory Press, Cold Spring Harbour, New York. USA, 2001.
- Salverda M L, De Visser J A, Barlow M. Natural evolution of *TEM-1* β -lactamase: experimental reconstruction and clinical relevance. *FEMS Microbiol. Rev.* 2010; 34: 1015–1036.
- Samaha Kfoury J M, Araj G F. Recent developments in β -lactamases and Extended spectrum β -lactamases. *Brit. Med. Jour.* 2003; 327:1209-1213.

Sanchez G V, Master R N, Karlowsky J A, Bordon J M. In vitro antimicrobial resistance of urinary *Escherichia coli* isolates among U.S. outpatients from 2000 to 2010. *Antimicrob. Agents Chemother.* 2012; 56: 2181-3.

Sandegren L, Lindqvist A, Kahlmeter G, Andersson D I. Nitrofurantoin resistance mechanism and fitness cost in *Escherichia coli*. *J. Antimicrob. Chemother.* 2008; 62: 495–503.

Sanders C C, Barry A L, Washington J A, Shubert C, Moland E S, Traczewski M M, Knapp C, Mulder R. Detection of Extended spectrum β -lactamase producing members of the family *Enterobacteriaceae* with Vitek ESBL test. *J. Clin. Microbiol.* 1996; 34: 2997–3001.

Sanguinetti M, Posteraro B, Spanu T, Ciccaglione D, Romano L, Fiori B, Nicoletti G, Zanetti S, Fadda G. Characterization of clinical isolates of *Enterobacteriaceae* from Italy by the BD Phoenix Extended spectrum β -lactamase detection method. *J. Clin. Microbiol.* 2003; 41: 1463– 1468.

Sarojamma V, Ramakrishna V. Prevalence of ESBL-Producing *Klebsiella pneumoniae* Isolates in Tertiary Care Hospital. *Inter. Schol. Res. Net. ISRN Microbiol.* 2011; 2011: 318348.

Sawai T, Mitsuhashi S, Yamagishi S. Drug resistance of enteric bacteria. XIV. Comparison of β -lactamases in gram negative rod bacteria resistant to aminobenzyl penicillin. *Jpn. J. Microbiol.* 1968; 12: 423–434.

Segatore B, Massidda O, Satta G, Setacci D, Amicosante G. High specificity of *cphA*-encoded metallo β -lactamase from *Aeromonas hydrophila* AE036 for carbapenems and its contribution to β -lactam resistance. *Antimicrob. Agents Chemother.* 1993; 37: 1324-1328.

Seiffert S N, Hilty M, Kronenberg A, Droz S, Perreten V V, Endimiani A. Extended spectrum cephalosporin resistant *E. coli* in community, specialized outpatient clinic and hospital setting in Switzerland. *J. Antimicrob. Chemother.* 2013; 88: 2249-54.

Shahid M, Malik A, Adil M, Jahan N, Malik R. Comparison of β -lactamase genes in clinical and food bacterial isolates in India. *J Infect Dev Ctries.* 2009; 3: 593-598.

Shahid M, Malik A. Plasmid mediated amikacin resistance in clinical isolates of *pseudomonas aeruginosa*. *Indian J Medical Microbiol.* 2004; 22: 182-184

Shukla I, Tiwari R, Agarawal M. Prevalence of Extended spectrum β -lactamases producing *Klebsiella pneumoniae* in a tertiary care hospital. *Indian J Med Microbiol.* 2004; 22: 87-91.

Singh N P, Goyal R. Changing trends in bacteriology of burns in burns unit, Delhi, India. *Burns.* 2003; 29: 129-132.

Sinha M, Srinivasa H. Antibiotic resistance profile and Extended spectrum β -lactamase (ESBL) production in *Acinetobacter* species. *Indian J Med Res.* 2007; 126: 63-67.

Sirot D, Sirot J. Transferable resistance to third generation cephalosporins in clinical isolates of *Klebsiella pneumoniae*: Identification of CTX-1, a novel β -lactamase. *J. Antimicrob Chemother.* 1987; 20: 323-34.

Sonnevend A, Al D K, Mag T, Herpay M, Kolodziejek J, Nowotny N, Usmani A, Sheikh F A, Pal T. CTX-M-15 producing multidrug resistant enteroaggregative *Escherichia coli* in the United Arab Emirates. *Clin. Microbiol. Infect.* 2006; 12: 582-585.

Steward C D, Wallace D, Hubert S K, Lawton R, Fridkin S K, Gaynes R P, McGowan J E, Tenover F C. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. *Diagn. Microbiol. Infect. Dis.* 2000; 38: 59–67.

Stokes H W, Gorman D B O, Recchia G D, Parskhian M, Hall R M. Structure and function of 59-base element recombination sites associated with mobile gene cassettes. *Mol. Microbiol.* 1997; 26; 731-745.

Stokes H W, Holmes A J, Nild B S, Holley M P, Nevalainen K M H, Mabbutt B C, Gillings M R. Gene Cassette PCR: Sequence Independent Recovery of Entire Genes from Environmental DNA. *Applied Environ Microbiol.* 2001; 67: 5240–5246.

Sturenburg E, Mack D. Extended spectrum β -lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. *J. Infect.* 2003; 47: 273-295.

Sumer S, Turk Dagi H, Findik D, Arslan U, AktugDemir N, Ural O, Tuncer I. Two outbreaks of ESBL producing *Klebsiella pneumoniae* in a neonatal intensive care unit. *Pediatr Int.* 2014; 56: 222-6.

Sun Y, Zeng Z, Chen S, Ma J, He L, Liu Y, Deng Y, Lei T, Zhao J, Liu JH. High prevalence of *bla*_{CTX-M} Extended-spectrum β -lactamase genes in *Escherichia coli* isolates from pets and emergence of CTXM-64 in China. *Clin Microbiol Infect.* 2010; 16; 1475–1481.

Swaminathan R. Antibiotic Sensitivity and Phenotypic Detection of ESBL producing *E. coli* Strains Causing Urinary Tract Infection In a Community Hospital, Chennai, Tamil Nadu, India. *Webmed Cent. Pharma. Sciences* 2012; 3: 1-15.

Sykes R B, Bush K. Physiology, biochemistry and inactivation of β -lactamases, In R. B. Morin and M. Gorman (ed.), the chemistry and biology of β -lactam antibiotics (3) Academic Press, London, England. 1982. p. 155-207.

Sykes R B, Matthew M. The β -lactamases of gram negative bacteria and their role in resistance to β -lactam antibiotics. *J. Antimicrob. Chemother.* 1976; 2: 115–157.

Tande D, Jallot N, Bougoudogo F, Montagnon T, Gouriou S, Sizun J. Extended spectrum β -lactamase producing Enterobacteriaceae in a Malian orphanage. *Emerg Infect Dis.* 2009; 15: 472-4.

Taneja N, Rao P, Arora J, Dogra A. Occurrence of ESBL & AmpC β -lactamases & susceptibility to newer antimicrobial agents in complicated UTI. *Indian J Med Res.* 2008; 127: 85-88.

Tellevik M G, Sollid J E, Blomberg G. Extended spectrum β -lactamase type SHV-12 producing Enterobacteriaceae causing septicemia in Tanzanian children: vectors for horizontal transfer of antimicrobial resistance. *Diagn Microbiol Infect Dis.* 2007; 59: 351-4.

Tenover F C. Mechanisms of antimicrobial resistance in bacteria. *Am. J. Med.* 2006; 119: S3-10.

Thamlikitkul V, Tiengrim S. In Vitro Activity of Biapenem against Gram negative bacteria isolated from Hospitalized Patients at Siriraj Hospital. *J Infect Dis Antimicrob Agents.* 2010; 27: 55-59.

Thomas, C. M. Paradigms of plasmid organization. *Mol. Microbiol.* 2000; 37: 485–491.

Toth A, Kocsis B, Damjanova I, Kristof K, Janvari L, Paszti J, Csercsik R, Topf J, Szabo D, Hamar P, Nagy N, Fuzi M. Fitness cost associated with resistance to fluoroquinolones is diverse across clones of *Klebsiella pneumoniae* and may select for CTX-M-15 type Extended spectrum β -lactamase. *Eur J Clin Microbiol Infect Dis*. 2014; 33: 837–843.

Tzelepi E, Giakkoupi P. Detection of Extended spectrum β -lactamases in clinical isolates of *Enterobacter cloacae* and *Enterobacter aerogenes*. *J Clin Microbiol*. 2000; 38: 542-546.

Uma devi S, Kandhakumari G, Joseph N M, Kumar S, Easow J M, Stephen S, Singh U K. Prevalence and antimicrobial susceptibility pattern of ESBL producing Gram Negative Bacilli. *J. Clin. Diag. Res*. 2011; 5: 236-239.

Upton A, Mohiuddin J, Bathgate T. High prevalence of *CTX-M-15* Extended spectrum β – lactamase among contacts of patients with shigellosis due to *Shigella flexneri* carrying *CTX-M-15*. *J Antimicrob. Chemother*. 2007; 60: 906-908.

Valverde A, Coque T M, Miguel L G. Complex molecular epidemiology of Extended spectrum β -lactamases in *Klebsiella pneumoniae*: a long term perspective from a single institution in Madrid. *J Antimicrob Chemother*. 2008; 61: 64-72.

Valverede A, Coque T M, Sanchez-Moreno M P. Dramatic increase in prevalence of fecal carriage of Extended Spectrum β -Lactamase Producing *Enterobacteriaceae* during non outbreak situations in Spain. *J Clin Microbiol*. 2004; 42: 4769-4775.

Van Elsas J D, Bailey M J. The ecology of transfer of mobile genetic elements. *FEMS Microbiol. Ecol*. 2002; 42: 187–197.

Venezia S N, Munz O H. Occurrence and phenotypic characteristics of Extended Spectrum β -Lactamases among members of the family *Enterobacteriaceae* at the Tel-Aviv Medical Centre (Israel) and evaluation of diagnostic tests. *J Clin Microbiol.* 2003; 41: 155–158.

Versalovic J, Koueth T, Lupski J R. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. *Nucleic Acid Res.* 1991; 19: 6823-6831.

Versalovic J, Schneider M, Bruijn F J, Lupski J R. Genomic fingerprinting of bacteria using Repetitive sequence based polymerase chain reaction. *Methods in Mol. and Cellular Biol.* 1994; 5: 25-40.

Vervoort J, Baraniak A, Gazin M, Sabirova J, Lammens C. Characterization of Two New CTX-M-25 Group Extended Spectrum β -Lactamase Variants Identified in *Escherichia coli* Isolates from Israel. *Plos One.* 2012; 7: 1-9.

Vignoli R, Varela G, Mota M I. Enteropathogenic *Escherichia coli* strains carrying genes encoding the *PER-2* and *TEM-116* Extended spectrum β -lactamases isolated from children with Diarrhea in Uruguay. *J Clin Microbiol.* 2005; 43: 2940–2943.

Vijayakanthi N, Bahl D, Kaur N, Maria A, Dubey N K. Frequency and Characteristics of Infections Caused by Extended-Spectrum β -Lactamase Producing Organisms in Neonates: A Prospective Cohort Study. Hindawi Publishing Corporation *BioMed Research International* 2013; 2013: 756209.

Villalon P, Valdezate S, Pascual M J M, Rubio V, Vindel A, Nieto J A S. Clonal Diversity of Nosocomial Epidemic *Acinetobacter baumannii* Strains Isolated in Spain. *J. Clinical Microbiol.* 2011; 49: 875–882.

Villegas M V, Kattan J N, Quinteros M G, Casellas J M. Prevalence of Extended spectrum β -lactamases in South America. *Clin Microbiol Infect.* 2008; 14: 154-8.

Kumar V, Neelagund Y F. Emergence of Extended spectrum β -lactamase mediated resistance in neonatal septicemia. *Indian J Pathol Microbiol.* 2006; 49: 616 – 9.

Kumar V, Neelagund Y F. Extended Spectrum β -Lactamase mediated resistance to third generation cephalosporins among *Klebsiella pneumoniae* in neonatal septicemia. *Indian Pediatr.* 2004; 41: 97-99.

Walsh T R, Toleman M A, Poirel L, Nordmann P. Metallo β -lactamases: the quiet before the storm? *Clin. Microbiol Rev.* 2005; 18: 306-25.

Walker T S. Antibacterial agents. *Text book of Microbiology.* W. B. Saunders Company. 1998. P-76-107.

Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases. *J. Antimicrob. Chemother.* 2006; 57: 373–383.

Wang J, Stephan R, Karczmarczyk M, Yan Q, Hachler H, Fanning S. Molecular characterization of *bla*_{ESBL} harboring conjugative plasmids identified in multidrug resistant *Escherichia coli* isolated from food producing animals and healthy humans. *Frontiers Microbiol.* 2013; 4: 9.

Warnes S L, Highmore C J, Keevil C W. Horizontal transfer of antibiotic resistance genes on abiotic touch surfaces: implications for public health. *Mol. Bio.* 2012; 3: e00489-12.

Weldhagen G F, Poirel L, Nordmann P. Ambler class A Extended spectrum β -lactamases in *Pseudomonas aeruginosae*: novel developments and clinical impact. *Antimicrob. Agents Chemother.* 2003; 47: 2385-2392.

Willey J M, Sherwood L M, Woolverton C J. *Antimicrobial Chemotherapy. A text book of Microbiology.* 7th Edition. McGraw Hill Companies. 2008. P-835-857.

Yin J, Cheng J, Sun Z, Ye Y, Gao Y F, Li J B, Zhang X J. Characterization of two plasmid-encoded cefotaximases found in clinical *Escherichia coli* isolates: CTX-M-65 and a novel enzyme, CTX-M-87. *J. Medical Microbiol.* 2009; 58: 811–815.

Zhanel G G, Johanson C, Embil J M, Noreddin A, Gin A, Vercaigne L, Hoban D J. Ertapenem: review of a new carbapenem. *Expert Rev. Anti Infect. Ther.* 2005; 3: 23–39.

Zhao W H, Hu Z Q. β -Lactamases identified in clinical isolates of *Pseudomonas aeruginosa*. *Crit. Rev. Microbiol.* 2010; 36: 245–258.

Zhao W H, Hu Z Q. β -lactamases in Gram-negative bacteria. *Crit. Rev. Microbiol.* 2013; 39: 79–101.

Zhou Y Y, Call D R, Broschat S L. Genetic relationships among 527 Gram negative bacterial plasmids. *Plasmid.* 2012; 68: 133–141.